Braveheart Bio

Brano Therapeutics

This company develops small-molecule inhibitors to treat heart failure and metabolic dysfunction for patients with cardiovascular diseases.

AnaCardio

This biopharmaceutical company develops oral small-molecule drugs to improve cardiac contractility in patients with heart failure.

Cardurion Pharmaceuticals

This clinical-stage biotechnology company develops therapeutic drugs for patients with heart failure and other cardiovascular diseases.

Myosin Therapeutics

This biopharmaceutical company develops small molecule therapies targeting molecular nanomotors to treat aggressive cancers and neurological disorders for patients with unmet medical needs.

Edgewise Therapeutics

This biopharmaceutical company develops small molecule therapies for patients with serious cardiovascular diseases and musculoskeletal conditions like Duchenne and Becker muscular dystrophy.

Imbria

This clinical-stage biotechnology company develops novel therapies targeting cardiac energy metabolism for patients with serious cardiovascular and metabolic diseases.

NanoPhoria

This company develops an inhalable nano-drug delivery platform and therapeutics for patients with heart failure and other cardiovascular diseases.

Cardior Pharmaceuticals

This biopharmaceutical company develops RNA-based therapeutics to prevent and repair heart disease for patients with conditions such as heart failure and myocardial infarction.